Welcome to our dedicated page for Alvotech Ordinary Shares news (Ticker: $ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alvotech Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alvotech Ordinary Shares's position in the market.
Rhea-AI Summary
Alvotech (ALVO) reports a 10% increase in total revenues in 2023, reaching $93.4 million, with product revenues soaring to $48.7 million. Key highlights include FDA approval of Simlandi™ biosimilar to Humira®, launch of Jamteki™ biosimilar to Stelara®, and positive results from clinical studies for proposed biosimilars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
-
Rhea-AI Summary
Alvotech (ALVO) announces the sale of 10,127,132 ordinary shares to investors for approximately USD 166 million. The transaction, valued at USD 16.41 per share, aims to strengthen the company's production capacity and support expected biosimilars launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
News
Rhea-AI Summary
Alvotech, a global biotech company, will release financial results for the full year 2023 and host a Capital Markets Day in Reykjavik on March 22, 2024. The company specializes in biosimilar medicines development and manufacture for patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
Rhea-AI Summary
Alvotech appoints Christina Siniscalchi as interim Chief Quality Officer, succeeding Sandra Casaca, to lead quality team after FDA facility inspection for biosimilar approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Alvotech, a biotech company, accepted an offer from investors to sell 10,127,132 ordinary shares for USD 166 million. The transaction is at a purchase price of USD 16.41 per share, aiming to use the proceeds for corporate purposes, production capacity, and biosimilar launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
-
Rhea-AI Summary
The FDA has approved SIMLANDI (adalimumab-ryvk) as an interchangeable biosimilar to Humira for various arthritis conditions and other diseases in the U.S., marking a significant milestone in Alvotech and Teva's strategic partnership. SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira with interchangeable exclusivity for the 40mg/0.4ml injection. The approval is based on a comprehensive clinical development program, positioning SIMLANDI to offer cost savings and additional treatment options for patients in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.74%
Tags
News
Rhea-AI Summary
Alvotech (ALVO) settles with Johnson & Johnson for AVT04 biosimilar to Stelara in Japan, Canada, and EEA. Market approvals granted, pending in the U.S. Launch dates set for various global markets. Commercial partners named for different regions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
-
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) announced positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to Prolia® and Xgeva®. The study assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, meeting its primary endpoints. Prolia® and Xgeva® are indicated for the treatment of bone disease, with combined net revenues worldwide from sales of Prolia and Xgeva over US$6 billion in the last twelve months before September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
-
Rhea-AI Summary
Alvotech (ALVO) announces the conclusion of the FDA reinspection of its facility in Iceland, receiving a form 483 with one observation. The company expects to provide a response to the FDA soon and aims to receive approval for AVT02 and AVT04 by February 24, 2024, and April 16, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
Rhea-AI Summary
Alvotech (ALVO) has announced the conclusion of the FDA reinspection of its facility in Iceland, receiving a form 483 with one observation. The company expects to provide a response to the FDA shortly and anticipates approval for AVT02 and AVT04 in the U.S. by February 24, 2024, and April 16, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
Alvotech Ordinary Shares
Nasdaq:ALVO
ALVO Rankings
ALVO Stock Data
3.87B
83.10M
72.34%
6.97%
0.07%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
Luxembourg
About ALVO
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a